CD274 and non-small cell lung carcinoma: Furthermore, the patient population evaluated here was representative of real-world NSCLC—comprised of patients whose NSCLC either relapsed or was refractory to anti–PD-(L)1 and other targeted treatments (if driver genomic aberrations were present)—whereas other anti–TIM-3/anti–PD-1 combination studies have only included a subset of ICI-experienced patients (37, 38).